Skip to main content
. Author manuscript; available in PMC: 2012 Oct 1.
Published in final edited form as: J Hepatol. 2011 Feb 18;55(4):838–845. doi: 10.1016/j.jhep.2010.12.043

Figure 3. Chemosensitivity of FACS-enriched HLE subpopulations.

Figure 3

Chemosensitivity of HLE subpopulations to cisplatin (A), doxorubicin (B) and sorafenib (C) was assayed with WST-1 reagent after treatment for 24 hours and expressed as optical density value per 100 μg protein content. *, **, *** p<0.05, 0.01 and 0.005 compared to HLE CD133+/ALDHhigh subpopulation.

HHS Vulnerability Disclosure